iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Dr Reddy’s Laboratories' stock surges ~4% on robust December quarter performance

27 Jan 2023 , 10:38 AM

Dr Reddy’s Laboratories’ counter was trading around 4% higher in Friday’s morning session as the company announced its results for the quarter ended December 2022.

Pharma major beat street estimates by announcing a 77% yoy jump in December 2022 quarter PAT at Rs1,247 crore, against a consolidated net profit of Rs706.50 crore in the corresponding quarter last year.

Total revenue from operations increased by 27% yoy to Rs6,770 crore, compared to Rs5,319.70 crore in the previous quarter.

EBITDA (earnings before interest, taxes, depreciation, and amortization) increased 14.3% year on year to Rs1,407.56 crore.

The global generics segment generated Rs5,924.10 crore in revenue. It grew 33% yoy and 6% sequentially, primarily due to new product launches, increased volumes in company’s core business, and favourable currency movement, offset partially by price erosion in its generic markets, according to the company.

Revenue increased by 64% yoy in North America, 6% in Europe, 10% in India, and 14% in emerging markets.

North American revenues totalled Rs30.6 billion. According to Dr Reddy’s Laboratories, it grew 64% year on year, driven by new product launches, volume increases, and favourable forex movement, which was partially offset by price erosion.

While revenues from the European and Indian markets were reported as Rs4.3 billion and Rs11.3 billion respectively.

Following this development, Dr Reddy’s counter was trading 3.42% higher at Rs4,344.60 apiece, against the previous close of Rs4,200.95 on NSE. The scrip opened at Rs4,280 and hit an intraday high of Rs4,380.90 so far in today’s trade.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Dr Reddys Laboratories
  • Q3FY23
  • revenue
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.